Docetaxel monotherapy in heavily pretreated metastatic breast cancer: A multicenter, community-based feasibility trial

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 1, 2001, Pages 57-62

  Schmidinger, M ^a   Budinsky, A C ^a   Wenzel, C ^a   Locker, G J ^a   Pluschnig, U ^a   Brodowicz, T ^a   Kubista, E ^a   Maca, S ^a   Zabernigg, A ^a   Ilsinger, P ^a   Seewann, L ^a   Hojas, S ^a   Blach, M ^a   Zielinski, C C ^a   Steger, G G ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anthracycline; Docetaxel; Metastatic breast cancer

Indexed keywords

COLONY STIMULATING FACTOR; DEXAMETHASONE; DOCETAXEL;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUID RETENTION; HUMAN; HUMAN TISSUE; LEUKOPENIA; LUNG DISEASE; MAJOR CLINICAL STUDY; METASTASIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; STOMATITIS; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; PACLITAXEL; TAXOIDS;

EID: 0034912384     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000204     Document Type: Article

References (36)

1. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: A preliminary report of the randomized phase III trial. 303 Study Group
2. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients
3. Docetaxel: Response in patients who have received at least two prior regimens for metastatic breast cancer
4. The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication
5. Adriamycin studies at the Istituto Nazionale Tumori Milan
6. Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: The French compassionate use programme experience
7. Docetaxel in advanced breast cancer, refractory to previous chemotherapy regimen including anthracycline
8. In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells
9. Docetaxel administered on a weekly basis for metastatic breast cancer
10. A phase II study of docetaxel as second and third line cytotoxic chemotherapy in disseminated breast cancer. Preliminary results
11. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: A phase II trial of the Clinical Cooperative Screening Group of the European Organization for Research and Treatment of Cancer
12. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: Reversibility, ligand stoichiometry, and competition
13. 2 as first-line chemotherapy for patients with advanced breast cancer: Report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer
14. Phase II trial of neoadjuvant docetaxel and cisplatin for the treatment of locally advanced breast cancer
15. An overview of phase II studies of docetaxel in patients with metastatic breast cancer
16. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients
17. A multicenter phase II trial of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC
18. Adriamycin in the treatment of advanced breast cancer: Studies by the Southwest Oncology Group
19. Multidisciplinary management of advanced primary and metastatic breast cancer
20. Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and resistant human ovarian carcinoma cell lines
21. Review of docetaxel and doxorubicin-based combinations in the management of breast cancer: From meta-static to adjuvant setting
22. A phase III trial comparing doxorubicin and docetaxel to doxorubicin and cyclophosphamide as first line chemotherapy for metastatic breast cancer
23. Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. UK Study Group
24. Docetaxel in advanced or metastatic breast cancer. A phase II South America experience
25. Taxotere: A second generation taxoid compound
26. Steroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the EORTC Drug Branch for Breast Cancer (IDBBC)
27. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
28. Studies with RP 56976 (Taxotere) A semisynthetic analogue of Taxol
29. 2 is effective but not feasible for some metastatic breast cancer patients heavily pretreated with chemotherapy - A phase II single center study
30. Docetaxel-cisplatin combination (DC) in patients with anthracycline-resistant advanced breast cancer
31. Preoperative docetaxel/epidoxorubicin in primary breast cancer
32. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer: A study of the EORTC Early Clinical Trials Group
33. Docetaxel in heavily pretreated metastatic breast cancer: Analysis of an international compassionate-use trial
34. Adriamycin in breast cancer: An overview of studies
35. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer
36. Phase II trial of docetaxel: A new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer